Study of Mirogabalin for Central Neuropathic Pain

NCT ID: NCT03901352

Last Updated: 2024-10-21

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

300 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-03-12

Study Completion Date

2020-12-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Investigate the efficacy and safety of mirogabalin in participants with central neuropathic pain in comparison to placebo

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

\[Double Blind Phase\] The primary objective is to compare change in the Average Daily Pain Score (ADPS) from baseline to Week 14 in Asian participants with central neuropathic pain (central neuropathic pain after spinal cord injury) receiving mirogabalin versus placebo.

\[Open Extension Phase\] The objective is to assess the long-term safety and efficacy of mirogabalin in participants with central neuropathic pain (central neuropathic pain after spinal cord injury, central post stroke pain, and central neuropathic pain in Parkinson's disease).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Central Neuropathic Pain

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Central neuropathic pain Developmental phase III

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

During the Double-blind Phase, participants will be randomized into parallel treatment arms.

During the Open Extension Phase, all participants will be assigned to a single group.
Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators
During the Double-blind Phase, masking will be triple (as shown above). During the Open Extension Phase, there will be no masking - the allocation is not applicable.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Mirogabalin

The patients with creatinine clearance (CLcr) ≥ 60 mL/min: Mirogabalin 20 mg or 30 mg, oral administration, Treatment period; 2-weeks titration and 12-weeks maintenance dose.

The patients with creatinine clearance (CLcr) 30 to \< 60 mL/min: Mirogabalin 10 mg or 15 mg, oral administration, Treatment period; 2-weeks titration and 12-weeks maintenance dose

Group Type EXPERIMENTAL

Mirogabalin

Intervention Type DRUG

Mirogabalin tablets for oral administration

Placebo

Placebo (14-weeks)

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Matching placebo tablets for oral administration

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Placebo

Matching placebo tablets for oral administration

Intervention Type DRUG

Mirogabalin

Mirogabalin tablets for oral administration

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Matching Placebo DS-5565

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Spinal cord injury (SCI) due to trauma
* American Spinal Injury Association impairment scale A, B, C, or D

Exclusion Criteria

* Other severe pain at screening or randomization, unrelated to central neuropathic pain after SCI, that may confound the assessment of central neuropathic pain after SCI
* Neurologic disorders at screening or randomization, unrelated to central neuropathic pain after SCI, that may confound the assessment of central neuropathic pain after SCI
* Major psychiatric disorders within 1 year prior to screening
Minimum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Daiichi Sankyo Co., Ltd.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Clinical Study Leader

Role: STUDY_DIRECTOR

Daiichi Sankyo

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Chubu-Rosai Hospital

Aichi, , Japan

Site Status

Social Medical Corporation Daido Clinic

Aichi, , Japan

Site Status

Honmachi Clinic

Aichi, , Japan

Site Status

Nagoya City West Medical Center

Aichi, , Japan

Site Status

Toyota Kosei Hospital

Aichi, , Japan

Site Status

Nagoya Tokushukai General Hospital

Aichi, , Japan

Site Status

Kainan Hospital

Aichi, , Japan

Site Status

Hachinohe City Hospital

Aomori, , Japan

Site Status

Hirosaki University Hospital

Aomori, , Japan

Site Status

Chiba University Hospital

Chiba, , Japan

Site Status

Chiba Rehabilitation Center

Chiba, , Japan

Site Status

Funabashi Municipal Medical Center

Chiba, , Japan

Site Status

Kimitsu Chuo Hospital

Chiba, , Japan

Site Status

Ehime Prefectural Central Hospital

Ehime, , Japan

Site Status

University of Fukui Hospital

Fukui, , Japan

Site Status

Fukui-ken Saiseikai Hospital

Fukui, , Japan

Site Status

Shin Komonji Hospital

Fukuoka, , Japan

Site Status

Kyushu Rosai Hospital

Fukuoka, , Japan

Site Status

Steel Memorial Yawata Hospital

Fukuoka, , Japan

Site Status

Go Neurosurgical Clinic

Fukuoka, , Japan

Site Status

Japan Organization of Occupational Health and Safety Spinal Injuries Center

Fukuoka, , Japan

Site Status

Shin Yukuhashi Hospital

Fukuoka, , Japan

Site Status

Fukushima Medical University Hospital

Fukushima, , Japan

Site Status

Southern TOHOKU Medical Clinic

Fukushima, , Japan

Site Status

Japanese Red Cross Maebashi Hospital

Gunma, , Japan

Site Status

Goodlife Hospital

Hiroshima, , Japan

Site Status

Medical Corporation Suiseikai Suiseikai Kajikawa Hospital

Hiroshima, , Japan

Site Status

Hiroshima City Asa Citizens Hospital

Hiroshima, , Japan

Site Status

Hiroshima Prefectural Hospital

Hiroshima, , Japan

Site Status

Teine Keijinkai Hospital

Hokkaido, , Japan

Site Status

Hakodate Municipal Hospital

Hokkaido, , Japan

Site Status

Sapporo Medical University Hospital

Hokkaido, , Japan

Site Status

Nakamura Memorial Hospital

Hokkaido, , Japan

Site Status

Sapporo City General Hospital

Hokkaido, , Japan

Site Status

Japanese Red Cross Asahikawa Hospital

Hokkaido, , Japan

Site Status

Hokkaido Spinal Cord Injury Center

Hokkaido, , Japan

Site Status

Kobe City Medical Center General Hospital

Hyōgo, , Japan

Site Status

Japanese Red Cross Kobe Hospital

Hyōgo, , Japan

Site Status

Hyogo Social Welfare Corporation Hyogo Rehabilitation Center Central Hospital

Hyōgo, , Japan

Site Status

Japanese Red Cross Society Himeji Hospital

Hyōgo, , Japan

Site Status

University of Tsukuba Hospital

Ibaraki, , Japan

Site Status

Ibaraki Seinan Medical Center Hospital

Ibaraki, , Japan

Site Status

Ishikawa Prefectural Central Hospital

Ishikawa, , Japan

Site Status

Kagawa Prefectural Central Hospital

Kagawa, , Japan

Site Status

Shikoku Medical Center for Children and Adults

Kagawa, , Japan

Site Status

Japan Organization of Occupational Health and Safety(JOHAS), Yokohama Rosai Hospital

Kanagawa, , Japan

Site Status

Yokohama City Minato Red Cross Hospital

Kanagawa, , Japan

Site Status

Yokohama City University Hospital

Kanagawa, , Japan

Site Status

Kanagawa Rehabilitation Hospital

Kanagawa, , Japan

Site Status

Sagamihara Kyodo Hospital

Kanagawa, , Japan

Site Status

National Hospital Organaization Kumamoto Medical Center

Kumamoto, , Japan

Site Status

Kumamoto Kinoh Hospital

Kumamoto, , Japan

Site Status

Kumamoto Takumadai Rehabilitation Hospital

Kumamoto, , Japan

Site Status

Kumamoto Rehabilitation Hospital

Kumamoto, , Japan

Site Status

Uji-Tokushukai Medical Center

Kyoto, , Japan

Site Status

Mie University Hospital

Mie, , Japan

Site Status

Tohoku Rosai Hospital

Miyagi, , Japan

Site Status

National Hospital Organization Sendai Medical Center

Miyagi, , Japan

Site Status

Katta General Hospital

Miyagi, , Japan

Site Status

Junwakai Memorial Hospital

Miyazaki, , Japan

Site Status

University of Miyazaki Hospital

Miyazaki, , Japan

Site Status

Japan Red Cross Society Azumino Hospital

Nagano, , Japan

Site Status

Nagasaki University Hospital

Nagasaki, , Japan

Site Status

Nagasaki Rosai Hospital

Nagasaki, , Japan

Site Status

Nara Prefecture General Rehabilitation Center

Nara, , Japan

Site Status

Japanese Red Cross Society Nagaoka Red Cross Hospital

Niigata, , Japan

Site Status

Nagaoka Chuo General Hospital

Niigata, , Japan

Site Status

Niigata City General Hospital

Niigata, , Japan

Site Status

Niigata University Medical & Dental Hospital

Niigata, , Japan

Site Status

Iwate Rehabilitation Center

Numakunai, , Japan

Site Status

Okayama City General Medical Center Okayama City Hospital

Okayama, , Japan

Site Status

Kibikogen Rehabilitation Center For Employment Injuries

Okayama, , Japan

Site Status

Medical Corporation Tapic Okinawa Rehabilitation Center Hospital

Okinawa, , Japan

Site Status

Osaka General Medical Center

Osaka, , Japan

Site Status

Osaka University Hospital

Osaka, , Japan

Site Status

Aijinkai Rehabilitation Hospital

Osaka, , Japan

Site Status

Osaka Rosai Hospital

Osaka, , Japan

Site Status

Medical Corporation Keiaikai Nakamura Hospital

Ōita, , Japan

Site Status

Saga-ken Medical Centre KOSEIKAN

Saga, , Japan

Site Status

Hanyu General Hospital

Saitama, , Japan

Site Status

Otsu City Hospital

Shiga, , Japan

Site Status

Saiseikai Shiga Hospital

Shiga, , Japan

Site Status

Shimane University Hospital

Shimane, , Japan

Site Status

Shizuoka City Shimizu Hospital

Shizuoka, , Japan

Site Status

Fujieda Municipal General Hospital

Shizuoka, , Japan

Site Status

Hamamatsu University Hospital

Shizuoka, , Japan

Site Status

Japanese Red Cross Hamamatsu Hospital

Shizuoka, , Japan

Site Status

Kikugawa General Hospital

Shizuoka, , Japan

Site Status

Dokkyo Medical University Hospital

Tochigi, , Japan

Site Status

Jichi Medical University Hospital

Tochigi, , Japan

Site Status

Tokushima University Hospital

Tokushima, , Japan

Site Status

Makita General Hospital

Tokyo, , Japan

Site Status

Nihon University Itabashi Hospital

Tokyo, , Japan

Site Status

National Hospital Organaization Murayama Medical Center

Tokyo, , Japan

Site Status

Tottori University Hospital

Tottori, , Japan

Site Status

Toyama University Hospital Hospital

Toyama, , Japan

Site Status

Wakayama Medical University Hospital

Wakayama, , Japan

Site Status

Sanyudo Rehabilitation Center

Yamagata, , Japan

Site Status

Yamaguchi University Hospital

Yamaguchi, , Japan

Site Status

Yamaguchi Rosai Hospital

Yamaguchi, , Japan

Site Status

Yamanashi Prefectural Central Hospital

Yamanashi, , Japan

Site Status

Daegu Fatima Hospital

Daegu, , South Korea

Site Status

Chungnam National University Hospital

Daejeon, , South Korea

Site Status

CHA Bundang Medical Center

Gyeonggi-do, , South Korea

Site Status

Seoul National University Bundang Hospital

Gyeonggi-do, , South Korea

Site Status

The Catholic University of Korea St. Vincent's Hospital

Gyeonggi-do, , South Korea

Site Status

Ajou University Hospital

Gyeonggi-do, , South Korea

Site Status

The Catholic University of Korea Incheon St. Mary's Hospital

Gyeonggi-do, , South Korea

Site Status

Chonbuk National University Hospital

Jeollabuk-do, , South Korea

Site Status

Pusan National University Hospital

Pusan, , South Korea

Site Status

Pusan National University Yangsan Hospital

Pusan, , South Korea

Site Status

Seoul Universtiy Hospital

Seoul, , South Korea

Site Status

The Catholic University of Korea Seoul St. Mary's Hospital

Seoul, , South Korea

Site Status

Samsung Medical Center

Seoul, , South Korea

Site Status

Hualien Tzu Chi Hospital

Hualien City, , Taiwan

Site Status

National Taiwan University Hospital

Taipei, , Taiwan

Site Status

Taipei Veterans General Hospital

Taipei, , Taiwan

Site Status

Chang Gung Memorial Hospital

Taoyuan District, , Taiwan

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Japan South Korea Taiwan

References

Explore related publications, articles, or registry entries linked to this study.

Hosomi K, Katayama Y, Sakoda H, Kikumori K, Kuroha M, Ushida T. Usefulness of Mirogabalin in Central Neuropathic Pain After Stroke: Post Hoc Analysis of a Phase 3 Study by Stroke Type and Location. Pain Ther. 2024 Oct;13(5):1151-1171. doi: 10.1007/s40122-024-00616-3. Epub 2024 Jul 4.

Reference Type DERIVED
PMID: 38963656 (View on PubMed)

Ushida T, Katayama Y, Hiasa Y, Nishihara M, Tajima F, Katoh S, Tanaka H, Maeda T, Furusawa K, Kakehi Y, Kikumori K, Kuroha M. Long-Term Safety and Efficacy of Mirogabalin for Central Neuropathic Pain: A Multinational, Phase 3, 52-Week, Open-Label Study in Asia. Pain Ther. 2023 Aug;12(4):963-978. doi: 10.1007/s40122-023-00513-1. Epub 2023 Apr 28.

Reference Type DERIVED
PMID: 37115464 (View on PubMed)

Ushida T, Katayama Y, Hiasa Y, Nishihara M, Tajima F, Katoh S, Tanaka H, Maeda T, Furusawa K, Richardson M, Kakehi Y, Kikumori K, Kuroha M. Mirogabalin for Central Neuropathic Pain After Spinal Cord Injury: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study in Asia. Neurology. 2023 Mar 14;100(11):e1193-e1206. doi: 10.1212/WNL.0000000000201709. Epub 2022 Dec 14.

Reference Type DERIVED
PMID: 36517235 (View on PubMed)

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

194653

Identifier Type: REGISTRY

Identifier Source: secondary_id

DS5565-A-J314

Identifier Type: -

Identifier Source: org_study_id